Literature DB >> 19797954

Utility of exhaled nitric oxide in the diagnosis and management of asthma.

Hashir Majid1, Christina Kao.   

Abstract

PURPOSE OF REVIEW: The fraction of nitric oxide in exhaled air (FeNO) is elevated in the presence of airway inflammation, and it may be a useful biomarker in asthma. The purpose of the present review is to highlight the current literature investigating the use of exhaled nitric oxide in the diagnosis and management of asthma. RECENT
FINDINGS: The measurement of exhaled nitric oxide has been studied in normal populations and in asthmatics. FeNO appears to be a useful screening tool for asthma, although nondisease factors may confound the interpretation of an elevated FeNO level. Clinical trials investigating the use of FeNO measurements in predicting asthma exacerbation and tailoring maintenance therapy have had varying success. Further studies incorporating individualized FeNO profiles into treatment algorithms are needed.
SUMMARY: FeNO shows promise as a tool in the diagnosis and treatment of asthma. However, further studies are needed to address outstanding questions about its exact role in guiding asthma management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19797954     DOI: 10.1097/MCP.0b013e328332ca46

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  9 in total

1.  Association between fraction of exhaled nitrous oxide, bronchodilator response and inhaled corticosteroid type.

Authors:  Ryan William Smith; Kim Downey; Nadia Snow; Sharon Dell; W Gary Smith
Journal:  Can Respir J       Date:  2015-04-15       Impact factor: 2.409

2.  Ability of Exhaled Nitric Oxide to Discriminate for Airflow Obstruction Among Frequent Exacerbators of Clinically Diagnosed Asthma.

Authors:  Leena Jalota; D Richard Allison; Vinisha Prajapati; Jose J Vempilly; Vipul V Jain
Journal:  Lung       Date:  2018-06-18       Impact factor: 2.584

Review 3.  Mechanistic impact of outdoor air pollution on asthma and allergic diseases.

Authors:  Shau-Ku Huang; Qingling Zhang; Zhiming Qiu; Kian Fan Chung
Journal:  J Thorac Dis       Date:  2015-01       Impact factor: 2.895

4.  Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients.

Authors:  Ziemowit Zietkowski; Maria M Tomasiak-Lozowska; Roman Skiepko; Elzbieta Zietkowska; Anna Bodzenta-Lukaszyk
Journal:  Respir Res       Date:  2010-08-12

5.  Significance of fractional exhaled nitric oxide combined with serum procalcitonin and C-reactive protein in evaluation of elderly asthma.

Authors:  Ji-Zhen Wu; Li-Jun Ma; Li-Min Zhao; Xiao-Yu Zhang; Xian-Liang Chen; Hong-Yan Kuang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

6.  Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.

Authors:  Brian J O'Connor; Sara Collarini; Gianluigi Poli; Caterina Brindicci; Monica Spinola; Daniela Acerbi; Peter J Barnes; Brian Leaker
Journal:  BMC Pulm Med       Date:  2011-12-21       Impact factor: 3.317

7.  The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma.

Authors:  Brian R Leaker; Dave Singh; Ferhana Y Ali; Peter J Barnes; Brian O'Connor
Journal:  BMC Pulm Med       Date:  2014-10-28       Impact factor: 3.317

Review 8.  Exhaled NO: Determinants and Clinical Application in Children With Allergic Airway Disease.

Authors:  Hyo Bin Kim; Sandrah P Eckel; Jeong Hee Kim; Frank D Gilliland
Journal:  Allergy Asthma Immunol Res       Date:  2015-07-02       Impact factor: 5.764

9.  Altered pattern of monocyte differentiation and monocyte-derived TGF-β1 in severe asthma.

Authors:  Chih-Hsing Hung; Chin-Chou Wang; Jau-Ling Suen; Chau-Chyun Sheu; Chang-Hung Kuo; Wei-Ting Liao; Yi-Hsin Yang; Chao-Chien Wu; Sum-Yee Leung; Ruay-Sheng Lai; Chi-Cheng Lin; Yu-Feng Wei; Chong-Yeh Lee; Ming-Shyan Huang; Shau-Ku Huang
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.